[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656638":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":30,"studyPopulation":23,"armGroups":31,"interventions":38,"overallOfficials":23,"centralContacts":44,"locations":50,"responsibleParty":68,"collaborators":23,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":23,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":23,"studyType":84,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":92,"whyStopped":23,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Number of steroid requiring exacerbations","Number of asthma exacerbations requiring the initiation of (or temporary increase in) systemic corticosteroids in severe eosinophilic asthma complicated by ABPA","26 weeks",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Patient-Reported Quality of Life as assessed by Saint George Respiratory Questionnaire","The change from baseline score in Saint George Respiratory Questionnaire. The Saint George Respiratory Questionnaire (SGRQ) total score ranges from 0 to 100. Higher scores indicate a worse outcome (greater health impairment\u002Fpoorer quality of life)",{"measure":18,"description":19,"timeFrame":12},"Asthma Control as assessed by Asthma Control Questionnaire 6","The change from baseline score in Asthma Control Questionnaire 6. ACQ-6 scores range from 0 to 6, where higher scores represent poorer asthma control. A score ≤0.75 indicates well-controlled asthma, while a score ≥1.5 indicates uncontrolled asthma.",{"measure":21,"description":22,"timeFrame":12},"Lung Function (FEV1)","The FEV1 change from baseline to End of Treatment",null,{"allocation":25,"interventionModel":26,"interventionModelDescription":23,"primaryPurpose":27,"observationalModel":23,"timePerspective":23,"maskingInfo":28},"NA","SINGLE_GROUP","TREATMENT",{"masking":29,"maskingDescription":23,"whoMasked":23},"NONE","Subjects who have been identified to have severe eosinophilic asthma with ABPA will be consented and enrolled in the study to receive Depemokimab injections (100 mg subcutaneous) administered every 6 months.",[32],{"label":33,"type":34,"description":35,"interventionNames":36},"Depemokimab treatment","EXPERIMENTAL","Depemokimab treatment will be given by injections administered every 6 months.",[37],"Drug: Depemokimab",[39],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":23},"DRUG","Depemokimab","100 mg (1mL) Subcutaneous Solution",[33],[45],{"name":46,"role":47,"phone":48,"phoneExt":23,"email":49},"Qian Qi","CONTACT","+8613706380314","qiqianqlh@163.com",[51],{"facility":52,"status":23,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China","Jinan","Shandong","250014","China","CN",{"type":59,"coordinates":60},"Point",[61,62],116.99722,36.66833,{"lat":62,"lon":61},[65],{"name":66,"role":47,"phone":67,"phoneExt":23,"email":49},"Qian Qi, Dr.","+86 13706380314",{"type":69,"investigatorFullName":46,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Prof.","100656638","real-world-effectiveness-of-depemokimab-in-allergic-bronchopulmonary-aspergillosis-with-severe-eosinophilic-asthma-100656638",false,"NCT07828327","Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma","Effectiveness and Safety of Depemokimab in Allergic Bronchopulmonary Aspergillosis (ABPA) With Severe Eosinophilic Asthma(SEA): a Prospective Study of Real-world Experience","Inclusion Criteria:\n\n* Female and Male patients aged 18-75 years\n* Diagnosis of Allergic Bronchopulmonary Aspergillosis (according to the ISHAM Working Group Diagnostic Criteria)\n* Severe asthma requiring treatment with high dose ICS plus a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control)\n\nExclusion Criteria:\n\n* History of allergy or hypersensitivity reaction to Depemokimab or any of its components.\n* Currently pregnant, breastfeeding, or lactating women.\n* Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.","ALL","18 Years","75 Years",{"count":82,"type":83},10,"ESTIMATED","INTERVENTIONAL",[25],"An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis",[88,89,90],"Allergic Bronchopulmonary Aspergillosis","ABPA","Severe Eosinophilic Asthma",[89,41],"NOT_YET_RECRUITING","2026-09-21",{"date":95,"type":96},"2026-09-24","ACTUAL",{"date":98,"type":83},"2026-11-01",{"date":100,"type":83},"2027-08-31",{"name":5,"class":6},1]